This article examines how different smoking cessation treatments, specifically varenicline and combination nicotine replacement therapy, may influence early abstinence by targeting key psychological mediators such as cravings and smoking expectancies.
Understanding these mechanisms can help improve treatment strategies and support public health efforts to reduce smoking rates.